Insiders Roundup: OncoCyte, BioSciences

The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “July 2019” and All Insider Sales to “$200,000+.”

According to these filters, the following are trades from company insiders last week.

10% owner Broadwood Partners LP bought one million shares of OncoCyte Corp. (OCX) for an average price of $2.0 per share on July 2.

The company which develops non-invasive, liquid biopsy diagnostics, has a market cap of $106.54 million and an enterprise value of $68.08 million. It has insider ownership of 23.53% and institutional ownership of 10.5%.

• Warning! GuruFocus has detected 4 Warning Signs with HDS. Click here to check it out.
• HDS 30-Year Financial Data
• The intrinsic value of HDS
• Peter Lynch Chart of HDS

Over the last 12 months, the stock has fallen 22% and is trading 70.38% below its 52-week high and 75.97% above its 52-week low.

ARCH Venture Partners IX LLC 10% owner, James Healy director and Robert Nelsen director and 10% owner of Karuna Therapeutics Inc. (KRTX), bought a combined 1.1 million shares for an average price of $16 per share on July 2. As of Friday, the stock was trading with a price of $27.

The company has a market cap of $572.44 million and an enterprise value of $561.70 million.

Over the last 12 months, the stock price has risen 22% and is trading 2.98% below its one-month high and 41.66% above its one month low.

Martine Werner, chairman, CEO and 10% owner, Jorge Combe, COO and 10% owner and Ortiz Guilermo director of DD3 Acquisition Corp. (DDMX), bought a combined 1,178,675 shares for an average price of $0.02 per share on July 02. As of Friday, the stock was trading with a price of $10.

The company has a market cap and an enterprise value of $72.52 million. It has institutional ownership of 9.49%.

Over the last 12 months, the stock price was stable and is trading 0.80% above its one-month low.

10% owner Larry N. Feinberg bought 1.03 million shares of Motus GI Holdings Inc. (MOTS) for an average price of $3.0 per share on July 1. As of Friday, the stock was trading with a price of $3.01.

The medical technology company has a market cap of $63.92 million and an enterprise value of $48.59 million. It has insider ownership of 2.53% and institutional ownership of 37.85%.

Over the last 12 months, the stock has fallen 65% and is trading 72.05% below its 52-week high and 27.35% above its 52-week low.

Most important insider sales

James Healy, director of Coherus BioSciences Inc. (CHRS), sold 360,000 shares for an average price of $22.30 per share on July 2.

The biotechnology company has a market cap of $1.62 billion and an enterprise value of $1.70 billion. It has insider ownership of 0.60% and institutional ownership of 86.91%.

Over the last three months, the stock has risen 61%. It is trading 0.26% below its 52-week high and 180.89% above its 52-week low.

George Vincent West, director sold 371,597 shares of Floor & Decor Holdings Inc. (FND) for an average price of $42 per share on July 2.

The company has a market cap of $4.12 billion and an enterprise value of $5.02 billion. It has insider ownership of 0.3% and institutional ownership of 99.97%.

Over the last 12 months, the stock has fallen 17% and is now trading 19.99% below its 52-week high and 79.91% above its 52-week low.

HD Supply Holdings Inc. (HDS)’s director, Jana Partners (Trades, Portfolio) LLC, sold 733,657 shares for an average price of $40.76 per share on July 02.

The industrial distributor has a market cap of $6.88 billion and an enterprise value of $9.39 billion. It has insider ownership of 0.42% and institutional ownership of 82.88%.

Over the last 12 months, the stock has fallen 6%. It is trading 14.60% below its 52-week high and 13.86% above its 52-week low.

Disclosure: I do not own any stocks mentioned.

About the author: